Skip to main content
RocheIn development

Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories

Source: Autobound Signal API · 93 signals tracked for Roche · updated

Get Roche's live signals in Claude or ChatGPT, or by API

AskWhat changed at Roche this week? Use Autobound signals for roche.com.

What happened

Roche is developing up to 22 additional Ionify assays on the cobas pro i 601 platform to expand its clinical mass spectrometry menu.

Source

Article excerpt

INDIANAPOLIS, Nov. 16, 2026 /PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY ) announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the cobas® pro i 601 platform with the Ionify® Gabapentin assay, components of its cobas® Mass Spec solution. Designed to bring advanced mass spectrometry testing into routine clinical laboratories, the solution combines the analytical capabilities of mass spectrometry with an automated, standardized workflow – expanding Roche's diagnostic menu into therapeutic drug monitoring. Mass spectrometry is widely used for clinical applications requiring highly sensitive and specific measurement, but traditional methods often involve specialized personnel and complex manual workflows. Roche is pioneering the transition of mass spectrometry from specialized reference facilities to the core laboratory, redefining complex testing into an accessible, standardized solution for routine clinical practice. Authorized through the De Novo pathway, the Ionify® Gabapentin assay adds a therapeutic drug monitoring application to a U.S. menu that includes 25-Hydroxy Vitamin D total and steroid hormone testing assays, such as estradiol and 17-Hydroxyprogesterone. Roche continues to develop additional clinical mass spectrometry assays to broaden the menu over time. Demonstrating an innovative, collaborative approach...

Keep reading with a free account

The rest of this article, and every signal for Roche, is in your free account.

Extracted from this sentence

The authorized PCCP includes the expansion of up to 22 Ionify® assays on the cobas® pro i 601 platform as PCCP requirements are met.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
Ionify assays
Location
Indianapolis, Indiana, United States

The full record

From the Signal API record

Details

Ticker
SIX:RO

Topics and mentions

Product tags

  • general technology
  • medical

Extraction

Confidence
85%
Detected
Nov 16, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Roche and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Roche this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/e1da68d2-5a70-33e6-e1cc-9a0071b81202 returns this record as JSON. POST /v1/companies/enrich returns every signal for roche.com.

{
  "signal_id": "e1da68d2-5a70-33e6-e1cc-9a0071b81202",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-16T14:00:00+00:00",
  "company": {
    "name": "Roche",
    "domain": "roche.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/roche-receives-fda-de-novo-authorization-for-cobas-pro-i-601-platform-with-ionify-gabapentin-assay-advancing-automated-mass-spectrometry-for-routine-clinical-laboratories-302939987.html",
    "title": "Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories",
    "ticker": "SIX:RO",
    "excerpt": "INDIANAPOLIS , Nov. 16, 2026 /PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY ) announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the cobas® pro i 601 platform with the Ionify® Gabapentin assay, components of its cobas® Mass Spec solution . Designed to bring advanced mass spectrometry testing into routine clinical laboratories, the solution combines the analytical capabilities of mass spectrometry with an automated, standardized workflow – expanding Roche's diagnostic menu into therapeutic drug monitoring. Mass spectrometry is widely used for clinical applications requiring highly sensitive and specific measurement, but traditional methods often involve specialized personnel and complex manual workflows. Roche is pioneering the transition of mass spectrometry from specialized reference facilities to the core laboratory, redefining complex testing into an accessible, standardized solution for routine clinical practice. Authorized through the De Novo pathway, the Ionify® Gabapentin assay adds a therapeutic drug monitoring application to a U.S. menu that includes 25-Hydroxy Vitamin D total and steroid hormone testing assays, such as estradiol and 17-Hydroxyprogesterone. Roche continues to develop additional clinical mass spectrometry assays to broaden the menu over time. Demonstrating an innovative, collaborative approach with...",
    "product": "Ionify assays",
    "summary": "Roche is developing up to 22 additional Ionify assays on the cobas pro i 601 platform to expand its clinical mass spectrometry menu.",
    "location": "Indianapolis, Indiana, United States",
    "planning": true,
    "image_url": "https://mmx.prnewswire.com/media/MS1964708/Roche_Logo_Blue_1400x957.jpg?id=OA3077652&p=facebook",
    "confidence": 0.85,
    "product_data": {
      "name": "Ionify assays",
      "full_text": "up to 22 Ionify® assays",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-11-16T14:00:00Z",
    "location_data": [
      {
        "city": "Indianapolis",
        "state": "Indiana",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "The authorized PCCP includes the expansion of up to 22 Ionify® assays on the cobas® pro i 601 platform as PCCP requirements are met."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.